| Cell cycle |
2.04 |
0.00e+0 |
110/124 (88.71%) |
CCND2;CCNB1;SMC1A;...
|
| Nucleotide excision repair |
1.97 |
4.62e-3 |
40/47 (85.11%) |
RAD23B;RPA1;PCNA;...
|
| Mismatch repair |
1.92 |
1.23e-2 |
22/23 (95.65%) |
RPA1;PCNA;RFC5;...
|
| IL-17 signaling pathway |
-1.64 |
4.65e-2 |
84/94 (89.36%) |
MAPK3;JUN;MAPK1;...
|
| Herpes simplex virus 1 infection |
-1.64 |
4.38e-2 |
165/498 (33.13%) |
PIK3CB;TNF;HLA-DOB;...
|
| Neomycin, kanamycin and gentamicin biosynthesis |
-1.65 |
4.38e-2 |
5/5 (100%) |
HK3;HK2
|
| Amoebiasis |
-1.65 |
4.39e-2 |
99/102 (97.06%) |
TGFB3;PRKCA;LAMA4;...
|
| Toxoplasmosis |
-1.66 |
4.50e-2 |
103/112 (91.96%) |
LAMA2;TNF;HLA-DOB;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-1.66 |
4.66e-2 |
97/100 (97%) |
PIK3CB;TNF;STAT5B;...
|
| Type I diabetes mellitus |
-1.66 |
4.89e-2 |
38/43 (88.37%) |
HLA-C;CD86;IL1A;...
|
| Influenza A |
-1.67 |
4.65e-2 |
156/172 (90.7%) |
PIK3CB;TNF;HLA-DOB;...
|
| Th17 cell differentiation |
-1.67 |
4.68e-2 |
95/107 (88.79%) |
PRKCQ;HLA-DOB;PPP3CA;...
|
| Cytosolic DNA-sensing pathway |
-1.68 |
4.70e-2 |
52/63 (82.54%) |
CHUK;RIPK1;MAVS;...
|
| Rheumatoid arthritis |
-1.68 |
4.41e-2 |
78/93 (83.87%) |
ATP6V1A;CD80;IL6;...
|
| C-type lectin receptor signaling pathway |
-1.69 |
4.56e-2 |
93/104 (89.42%) |
MAPK3;JUN;PLK3;...
|
| Graft-versus-host disease |
-1.70 |
4.36e-2 |
32/42 (76.19%) |
CD80;IL6;HLA-C;...
|
| TNF signaling pathway |
-1.71 |
3.88e-2 |
103/112 (91.96%) |
CX3CL1;CREB1;PIK3CB;...
|
| Phagosome |
-1.74 |
2.98e-2 |
118/152 (77.63%) |
TUBB2A;TAP2;HLA-F;...
|
| Osteoclast differentiation |
-1.74 |
3.16e-2 |
117/127 (92.13%) |
CREB1;PIK3CB;TNF;...
|
| Malaria |
-1.75 |
3.37e-2 |
44/50 (88%) |
ACKR1;SDC1;TGFB3;...
|
| NOD-like receptor signaling pathway |
-1.76 |
3.16e-2 |
145/181 (80.11%) |
TNF;MAP3K7;BIRC2;...
|
| Asthma |
-1.78 |
2.37e-2 |
25/31 (80.65%) |
CD40;CD40LG;FCER1G;...
|
| Tuberculosis |
-1.81 |
1.95e-2 |
159/180 (88.33%) |
MAPK13;IL10RA;IL6;...
|
| Neutrophil extracellular trap formation |
-1.82 |
1.75e-2 |
101/189 (53.44%) |
PIK3CB;MAP3K7;PLCB2;...
|
| ECM-receptor interaction |
-1.92 |
6.31e-3 |
80/88 (90.91%) |
COL1A1;GP1BA;ITGA5;...
|
| Toll-like receptor signaling pathway |
-1.95 |
5.26e-3 |
94/104 (90.38%) |
PIK3CB;TNF;MAP3K7;...
|
| Protein digestion and absorption |
-2.00 |
3.51e-3 |
78/103 (75.73%) |
COL13A1;SLC3A2;CTRL;...
|
| Complement and coagulation cascades |
-2.00 |
5.26e-3 |
76/85 (89.41%) |
PROC;SERPINE1;C5;...
|
| Leishmaniasis |
-2.07 |
1.05e-2 |
67/77 (87.01%) |
MAPK14;IL1A;NFKB1;...
|
